FindTrial
Sign In

Stereotactic Ablative Body Radiotherapy (SABR)

RADIATION5 trials

Sponsors

Memorial Sloan Kettering Cancer Center, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, University College, London, Peking University First Hospital, University Health Network, Toronto

Conditions

Borderline Resectable Pancreatic AdenocarcinomaEarly Hepatocellular CarcinomaImmunotherapyPancreatic AdenocarcinomaProstate Cancer MetastaticRadiation TherapyRenal Cancer MetastaticResectable Pancreatic Adenocarcinoma

Phase 1

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Active, not recruitingNCT03245541
Memorial Sloan Kettering Cancer CenterPancreatic Adenocarcinoma
Start: 2020-08-14End: 2026-09-30Updated: 2025-10-07

Phase 2

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
RecruitingNCT06889649
Peking University First HospitalImmunotherapy, Radiation Therapy, Renal Cancer Metastatic +1
Start: 2019-01-01End: 2028-02-20Target: 30Updated: 2025-03-21

Phase 3

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
RecruitingNCT06320067
University College, LondonProstate Cancer Metastatic
Start: 2024-06-11End: 2032-03-31Target: 3360Updated: 2025-09-26

Unknown Phase

Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma
NCT04915417
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sBorderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Start: 2021-08-01End: 2024-08-01Target: 30Updated: 2021-06-22
A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
RecruitingNCT07628751
University Health Network, TorontoEarly Hepatocellular Carcinoma
Start: 2026-05-11End: 2032-04-01Target: 218Updated: 2026-06-05

Related Papers

Efficacy and safety of SABR/partial‑SABR combined with axitinib and toripalimab in recurrent or metastatic renal cell carcinoma: Preliminary results from a prospective phase 2 trial
Oncology Letters2025-06-02
METANOVA: A phase II trial of metastasis-directed radiotherapy for de novo oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial.
Journal of Clinical Oncology2025-05-28
Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights.
Journal of Clinical Oncology2024-06-01
The quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications
BJR|Open2023-12-123 citations
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.
Journal of Clinical Oncology2023-06-013 citations
A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).
Journal of Clinical Oncology2023-01-241 citations
Abstract B58: A phase I/II study of durvalumab and stereotactic radiotherapy in locally advanced pancreatic cancer
Cancer Research2019-12-135 citations
DNA repair deficiency, genomic instability and immune profiling in a phase 1 study of locally advanced pancreatic cancer patients treated with veliparib, gemcitabine and radiotherapy.
Journal of Clinical Oncology2018-05-20